ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,842.91
      0.11%
      US Tech 100
      20,203.20
      0.00%
      Dow Jones
      42,518.28
      0.52%
      Brent Oil
      79.685
      -0.02%
      Bitcoin
      97,347.19
      0.87%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Carisma Therapeutics Inc (CARM) Quote

      Carisma Therapeutics Inc

      Carisma Therapeutics Inc (CARM)

      Carmanah Minerals Corp
      Carrefour Property Development
      0.4548
      0.00
      (0.00%)
      Closed January 15 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      0.4548
      Bid
      0.40
      Ask
      0.48
      Volume
      -
      0.00 Day's Range 0.00
      0.38 52 Week Range 2.77
      Market Cap
      18.988M
      Previous Close
      0.4548
      Open
      -
      Last Trade
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      269,268
      Shares Outstanding
      41,750,109
      Dividend Yield
      -
      PE Ratio
      -0.22
      Earnings Per Share (EPS)
      -2.08
      Revenue
      14.92M
      Net Profit
      -86.88M

      About Carisma Therapeutics Inc

      Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company's lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company's second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.carismatx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Carisma Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CARM. The last closing price for Carisma Therapeutics was $0.45. Over the last year, Carisma Therapeutics shares have traded in a share price range of $ 0.38 to $ 2.77.

      Carisma Therapeutics currently has 41,750,109 shares outstanding. The market capitalization of Carisma Therapeutics is $18.99 million. Carisma Therapeutics has a price to earnings ratio (PE ratio) of -0.22.

      Ask ADVFN Intelligence (AI)

      CARM Latest News

      More News

      Carmila: Resources Devoted to the Liquidity Contract as of 31 December 2024

      Regulatory News: At 31 December 2024, resources made available for the liquidity agreement concluded by Carmila (Paris:CARM) with Kepler Chevreux were the following: - 45,945 CARMILA shares;...

      15 hours ago
      Business Wire

      Form 8-K - Current report

      January 13 2025
      Edgar (US Regulatory)

      Form 8-K - Current report

      January 10 2025
      Edgar (US Regulatory)

      Carmila Will Publish Its 2024 Full-year Results on Tuesday, February 11, 2025, After Market Close

      Regulatory News: Carmila (Paris:CARM) will publish its 2024 full-year results on Tuesday, February 11, 2025, after market close and will present the 2024 full-year results on Wednesday, February...

      January 09 2025
      Business Wire

      Form 3 - Initial statement of beneficial ownership of securities

      January 02 2025
      Edgar (US Regulatory)

      Form 8-K - Current report

      December 26 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.0652-12.53846153850.520.520.42731361530.46051085CS
      4-0.0122-2.612419700210.4670.61790.382943800.46132822CS
      12-0.525-53.58236374770.97981.130.382692680.65379395CS
      26-0.7752-63.02439024391.231.380.382127920.82883503CS
      52-2.0952-82.16470588242.552.770.383376601.34774594CS
      156-5.3352-92.14507772025.799.76620.382920452.79510984CS
      260-5.3352-92.14507772025.799.76620.382920452.79510984CS

      CARM - Frequently Asked Questions (FAQ)

      What is the current Carisma Therapeutics share price?
      The current share price of Carisma Therapeutics is $ 0.4548
      How many Carisma Therapeutics shares are in issue?
      Carisma Therapeutics has 41,750,109 shares in issue
      What is the market cap of Carisma Therapeutics?
      The market capitalisation of Carisma Therapeutics is USD 18.99M
      What is the 1 year trading range for Carisma Therapeutics share price?
      Carisma Therapeutics has traded in the range of $ 0.38 to $ 2.77 during the past year
      What is the PE ratio of Carisma Therapeutics?
      The price to earnings ratio of Carisma Therapeutics is -0.22
      What is the cash to sales ratio of Carisma Therapeutics?
      The cash to sales ratio of Carisma Therapeutics is 1.26
      What is the reporting currency for Carisma Therapeutics?
      Carisma Therapeutics reports financial results in USD
      What is the latest annual turnover for Carisma Therapeutics?
      The latest annual turnover of Carisma Therapeutics is USD 14.92M
      What is the latest annual profit for Carisma Therapeutics?
      The latest annual profit of Carisma Therapeutics is USD -86.88M
      What is the registered address of Carisma Therapeutics?
      The registered address for Carisma Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Carisma Therapeutics website address?
      The website address for Carisma Therapeutics is www.carismatx.com
      Which industry sector does Carisma Therapeutics operate in?
      Carisma Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AALAmerican Airlines Group Inc
      $ 18.21
      (0.00%)
      		0
      AAGRAfrican Agriculture Holdings Inc
      $ 0.1326
      (0.00%)
      		0
      AADRAdvisorShares Dorsey Wright ADR ETF
      $ 71.1249
      (0.00%)
      		0
      AADIAadi Bioscience Inc
      $ 2.995
      (0.00%)
      		0
      AACGATA Creativity Global
      $ 0.91995
      (0.00%)
      		0
      AALAmerican Airlines Group Inc
      $ 18.21
      (0.00%)
      		0
      AAGRAfrican Agriculture Holdings Inc
      $ 0.1326
      (0.00%)
      		0
      AADRAdvisorShares Dorsey Wright ADR ETF
      $ 71.1249
      (0.00%)
      		0
      AADIAadi Bioscience Inc
      $ 2.995
      (0.00%)
      		0
      AACGATA Creativity Global
      $ 0.91995
      (0.00%)
      		0
      AALAmerican Airlines Group Inc
      $ 18.21
      (0.00%)
      		0
      AAGRAfrican Agriculture Holdings Inc
      $ 0.1326
      (0.00%)
      		0
      AADRAdvisorShares Dorsey Wright ADR ETF
      $ 71.1249
      (0.00%)
      		0
      AADIAadi Bioscience Inc
      $ 2.995
      (0.00%)
      		0
      AACGATA Creativity Global
      $ 0.91995
      (0.00%)
      		0

      CARM Discussion

      View Posts
      PonkenPlonken PonkenPlonken 4 months ago
      I appreciate you reaching out. I like to follow the money in bioland or predict where it might go. Hence i really like this. Their CAR M CD47 approach is not new and many wished for these trials. The risk however is huge hence no one bit this (monotherapy trial with safety as primary endpoint is almost random)

      I am having a very close eye on this as they will share the first clinical data in q4. Any price increase prior might hint at things being right/a rally coming. The problem is, this is monotherapy only and not the one where they combine with the mRNA tech (which is likely where the good stuff is)

      So down the road we will be getting some great hints here on whether this might be "THE next big thing" or not.... A LOT of targets nominated by them...
      👍️0
      jondoeuk jondoeuk 4 months ago
      From this: “Without a doubt there's big biological risk here,” says Carisma CSO Michael Klichinsky. Researchers have yet to prove either the efficacy or the approvability of CAR macrophages. But solid tumours account for 90% of the cancer burden, making the possibility of activity in these settings with an in vivo reprogramming agent all the more appealing. “We’re going after a real unmet need,” he adds. https://www.nature.com/articles/d41573-024-00150-z
      👍️0
      Prestotic Prestotic 5 months ago
      Vdog, your dog stock shedding another 8.33% today on a pathetic 2 million shares. Going to trips withou a contract soon. Hope you get this message. You could be in Carisma if only you listened.
      👍️0
      Prestotic Prestotic 5 months ago
      Vdog has no Carisma Therapeutics. Losers like him love losers like VXIT. Carisma up 50 % in 2 weeks, Vxit down 50%. LOVE to say I TOLD YOU SO! How's your DD treating you JA
      👍️0
      Prestotic Prestotic 5 months ago
      Eat shi* vdog
      👍️0
      Prestotic Prestotic 5 months ago
      Another 50,000 getting accumulated/ covered @ $1.04. To the moon, soon.
      👍️0
      Prestotic Prestotic 5 months ago
      No noise here because Carisma is not a penny stock. This has moved nicely off of the bottom of .80 from last week. Plus 20%. Positive results from phase 2 study will solidify deal with Moderna and get this back up to levels seen mid June. Today's action, including buy, buy, buy of 75000 shares at 3:30 pm shows accumulation, or at least some worried shorts covering. Looking for strong move up on phase 2 results.
      👍️0
      Prestotic Prestotic 5 months ago
      No noise here because Carisma in not a penny stock. This has moved nicely off of the bottom of .80 from last week. Plus 20%. Positive results from phase 2 study will solidify deal with Moderna and get this back up to levels seen mid July. Today's action, including buy, buy, buy of 75000 shares around 2pm shows accumulation, or at least something worried shorts covering. Looking for strong move up on phase 2 results.
      👍️0
      CancunCharlie CancunCharlie 5 months ago
      Is there anyone here?? No comments in over a month. I think this looks good, but I'm wondering why it's so quite here.
      👍️0
      PonkenPlonken PonkenPlonken 6 months ago
      pretty strong
      nice tech$
      👍️0
      glenn1919 glenn1919 7 months ago
      CARM.......................https://stockcharts.com/h-sc/ui?s=CARM&p=W&b=5&g=0&id=p86431144783
      👍️0
      Awl416 Awl416 7 months ago
      Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
      👍️0
      Termite7 Termite7 8 months ago
      Could it be CARM under $0.30 ....???.......Thanks!!!
      👍️0
      axelvento axelvento 8 months ago
      $1.46 bouncer
      👍️0
      PonkenPlonken PonkenPlonken 9 months ago
      https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00537-x
      MRNA provides the tech, 3bln + in biobucks and has not so distant private relative with TOP tier c suite.
      👍️0
      Monksdream Monksdream 10 months ago
      CARM under $3
      👍️0
      mrplmer mrplmer 1 year ago
      Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
      👍️0
      mrplmer mrplmer 1 year ago
      Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
      👍️0
      81vette 81vette 1 year ago
      1st higher high today and bid growing now,I got some 2.64,will see if dump continues or not
      👍️0
      81vette 81vette 1 year ago
      Yea,distribution only so far today,I am watching for accumulation to start after this dumpathon,short interest went up 300% today also, 100k now,no sign of institutional buying yet,they currently hold 19%
      👍️0
      stock1ace1 stock1ace1 1 year ago
      Red on news .. we no what that means lol
      👍️0
      81vette 81vette 1 year ago
      Deal with Moderna for cancer cures,institutional might buy now lol,went up last time on this news,analysts target $9.50,short 2.45M,not optionable is good,gap filled down now,52 week low 2 weeks ago
      👍️0

      Your Recent History

      NASDAQ
      CARM
      Carisma Therapeutics
      NYSE
      WES
      Western Midstream Partners
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads